Company Overview and News

 
Toyota takes "most reputable" crown ahead of Air NZ

3h radionz.co.nz
The car manufacturer Toyota has overthrown Air New Zealand in being ranked the country's most reputable and trusted corporation.

 
NZ shares rise led by Synlait, A2, Comvita as US earnings stoke global sentiment

5h nzherald.co.nz
New Zealand shares gained as the US earnings season helped lift sentiment toward equities. Growth-linked companies including Synlait Milk, A2 Milk, Comvita led gains in the local market.

 
Toyota tops corporate reputation index

18h nzherald.co.nz
Toyota New Zealand has taken top spot as having the strongest corporate reputation in New Zealand.

 
MARKET WRAP: Sky TV lower as Spark benefits from rugby rights

2018-04-18 nbr.co.nz
Fat Prophets head of research Greg Smith says "Spark and TVNZ’s win is Sky TVs loss,”

 
NZ shares gain; Trade Me rises

2018-04-18 nzherald.co.nz
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.

 
Fletcher Building's Formica and Roof Tile operations worth about $700m

2018-04-18 nzherald.co.nz
Fletcher Building's Formica and Roof Tile businesses are worth about $700 million and would sell at a higher multiple than other parts of the group, say analysts at Morningstar.

 
Deals of the day-Mergers and acquisitions

2018-04-17 reuters
April 17 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Tuesday: ** Concert ticketing firm CTS Eventim said on Tuesday it had bought a controlling stake in Vivo Concerti, an Italian promoter of concerts and musicals. ** Neoenergia SA, Brazil’s largest utility by number of customers, has offered to acquire a stake in Brazilian power distribution company Eletropaulo Metropolitana SA

 
Shares fall as investors weight up Fletcher rights issue

2018-04-17 nzherald.co.nz
New Zealand shares fell as investors weighed up the impact of Fletcher Building's deeply discounted rights issue soaking up demand from the broader market. Auckland International Airport and exporters A2 Milk Co and Comvita dropped.

 
Wesfarmers squashes talk of Fletcher Building stake

2018-04-17 theage.com.au
Wesfarmers has squashed speculation that it has bought a stake in struggling New Zealand-based construction and materials company Fletcher Building.

 
Wesfarmers squashes talk of Fletcher Building stake

2018-04-17 smh.com.au
Wesfarmers has squashed speculation that it has bought a stake in struggling New Zealand-based construction and materials company Fletcher Building.

 
Puhoi-to-Warkworth PPP roading contract a nil-margin deal for Fletcher

2018-04-17 nzherald.co.nz
Fletcher Building says the company is currently making zero profit from the Puhoi-to-Warkworth roading contract it holds as part of the NX2 consortium.

 
Fletcher Building moves to patch up finances

2018-04-17 radionz.co.nz
Fletcher Building is to beef up its finance with a $750 million share sale and a sale of some businesses.

 
Fletcher Building says underwriting costs deliver certainty

2018-04-17 nbr.co.nz
Credit card details are required to authenticate your account. You won't be charged until your trial has ended. Cancel anytime.

 
NZ institutional investors welcome Fletcher move: price 'compelling'

2018-04-16 nzherald.co.nz
New Zealand institutional investors have welcomed Fletcher Building's $750 million rights issue, saying it should put the business in a better financial position and the rights issue price was "compelling".

 
Fletcher to raise $750m from rights issue and sell Formica, Roof Tile Group

2018-04-16 nbr.co.nz
Fletcher Building says it will raise $750 million in fresh equity through a fully underwritten 1-for-4.46 rights issue priced at $4.80 per share and is planning to sell its Formica and Roof Tile Group businesses.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...